IN2014MN02522A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02522A
IN2014MN02522A IN2522MUN2014A IN2014MN02522A IN 2014MN02522 A IN2014MN02522 A IN 2014MN02522A IN 2522MUN2014 A IN2522MUN2014 A IN 2522MUN2014A IN 2014MN02522 A IN2014MN02522 A IN 2014MN02522A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Michael Baumann
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of IN2014MN02522A publication Critical patent/IN2014MN02522A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/49Platelet-derived growth factor [PDGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2522MUN2014 2012-06-28 2014-12-11 IN2014MN02522A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12174020 2012-06-28
PCT/EP2013/063488 WO2014001442A1 (en) 2012-06-28 2013-06-27 Designed ankyrin repeat proteins binding to platelet-derived growth factor

Publications (1)

Publication Number Publication Date
IN2014MN02522A true IN2014MN02522A (enExample) 2015-07-17

Family

ID=48699826

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2522MUN2014 IN2014MN02522A (enExample) 2012-06-28 2014-12-11

Country Status (16)

Country Link
US (2) US9163070B2 (enExample)
EP (1) EP2867360B1 (enExample)
JP (1) JP2015522576A (enExample)
KR (1) KR20150023957A (enExample)
CN (1) CN104508129A (enExample)
AU (1) AU2013283296A1 (enExample)
BR (1) BR112014032316A2 (enExample)
CA (1) CA2877584A1 (enExample)
HK (1) HK1209156A1 (enExample)
IL (1) IL236428A0 (enExample)
IN (1) IN2014MN02522A (enExample)
MX (1) MX2014015825A (enExample)
RU (1) RU2014150224A (enExample)
SG (1) SG11201408196RA (enExample)
WO (1) WO2014001442A1 (enExample)
ZA (1) ZA201408872B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
DK2643349T3 (da) 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
CN106605228B (zh) 2014-07-07 2019-08-16 耶达研究及发展有限公司 计算蛋白质设计的方法
US20170226158A1 (en) * 2014-08-11 2017-08-10 Medimmune Limited Intracellular antigen binding
JP2017534644A (ja) 2014-11-10 2017-11-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗ang2抗体及び使用方法
RU2017120360A (ru) 2014-11-10 2018-12-13 Ф.Хоффманн-Ля Рош Аг Биспецифические антитела и способы их применения в офтальмологии
SG11201703426PA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Anti-pdgf-b antibodies and methods of use
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
PH12017501792B1 (en) 2015-04-02 2022-07-20 Molecular Partners Ag Recombinant binding proteins and their use
US10283384B2 (en) * 2015-04-27 2019-05-07 Taiwan Semiconductor Manufacturing Co., Ltd. Method for etching etch layer and wafer etching apparatus
AU2017331329B2 (en) 2016-09-22 2020-10-29 Molecular Partners Ag Recombinant binding proteins and their use
US10037890B2 (en) * 2016-10-11 2018-07-31 Lam Research Corporation Method for selectively etching with reduced aspect ratio dependence
US11127483B2 (en) 2017-03-07 2021-09-21 Igc Bio, Inc. Computational pipeline for antibody modeling and design
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2019180243A1 (en) 2018-03-22 2019-09-26 Charité-Universitätsmedizin Berlin Crispr associated protein reactive t cell immunity
EP3807401A1 (en) 2018-06-15 2021-04-21 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
MX2021004012A (es) 2018-10-08 2021-06-23 Univ Zuerich Polipeptidos tetramericos de union a her2.
US20220017433A1 (en) 2018-11-21 2022-01-20 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
WO2020144378A1 (en) 2019-01-11 2020-07-16 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
EP3953712A1 (en) 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
SG11202112925PA (en) * 2019-06-04 2021-12-30 Molecular Partners Ag Recombinant fap binding proteins and their use
US20220298212A1 (en) * 2019-06-04 2022-09-22 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
AR119080A1 (es) 2019-06-04 2021-11-24 Molecular Partners Ag Proteínas multiespecíficas
WO2021044050A1 (en) 2019-09-05 2021-03-11 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
CN114929730A (zh) 2019-12-11 2022-08-19 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
WO2021204781A1 (en) 2020-04-06 2021-10-14 Universität Zürich Artc1 ligands for cancer treatment
WO2021224686A1 (en) 2020-05-06 2021-11-11 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
JP2023528204A (ja) 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
KR20230048151A (ko) 2020-08-18 2023-04-10 유니버시타트 취리히 Cd25 편향된 항-il-2 항체
WO2022130300A1 (en) 2020-12-16 2022-06-23 Molecular Partners Ag Novel slow-release prodrugs
US20240310378A1 (en) 2021-02-11 2024-09-19 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
WO2022190018A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
AU2022232216A1 (en) 2021-03-09 2023-10-05 Molecular Partners Ag Protease cleavable prodrugs
KR20230155464A (ko) 2021-03-09 2023-11-10 몰리큘라 파트너스 아게 신규한 DARPin-기반 다중특이성 T-세포 인게이저
JP2024508969A (ja) 2021-03-09 2024-02-28 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のDARPinに基づくCD33エンゲージャ
KR20240045260A (ko) 2021-08-05 2024-04-05 이뮤노스 테라퓨틱스 아게 Hla 융합 단백질을 포함하는 복합 치료제
IL310615A (en) 2021-08-05 2024-04-01 Immunos Therapeutics Ag Pharmaceutical compositions comprising HLA fusion proteins
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024133013A1 (en) 2022-12-19 2024-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Means and methods to target endogenous condensates
EP4662230A1 (en) 2023-02-08 2025-12-17 ImmunOs Therapeutics AG Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2025008519A1 (en) 2023-07-05 2025-01-09 Universität Bern Il-1ra blockers for treatment and prevention of sepsis
WO2025021293A1 (en) 2023-07-25 2025-01-30 Universität Zürich Disruption of rbr1 expression in plant cells
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025202503A1 (en) 2024-03-28 2025-10-02 Universität Zürich Extracellular vesicles carrying cancer specific splice variants

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE69834032T2 (de) 1997-04-23 2006-12-07 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
HK1039355B (en) 1998-12-02 2007-09-21 Bristol-Myers Squibb Company Dna-protein fusions and uses thereof
US7417130B2 (en) * 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
CA2460587A1 (en) * 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
NZ601544A (en) * 2003-08-27 2013-11-29 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
JP2008519590A (ja) * 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
US7875465B2 (en) * 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
PL2173890T3 (pl) 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
DE112008003232T5 (de) * 2007-11-30 2011-02-24 Glaxo Group Limited, Greenford Antigen-Bindungskonstrukte
WO2009100990A1 (en) * 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Process for the production of a peptide
US20110262964A1 (en) * 2008-03-19 2011-10-27 Hugues Bedouelle Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
DK2643349T3 (da) 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
KR20140039203A (ko) * 2011-04-29 2014-04-01 얀센 바이오테크 인코포레이티드 Il4/il13 결합 반복 단백질 및 용도

Also Published As

Publication number Publication date
AU2013283296A1 (en) 2015-02-05
BR112014032316A2 (pt) 2017-06-27
US20140005125A1 (en) 2014-01-02
KR20150023957A (ko) 2015-03-05
ZA201408872B (en) 2016-05-25
CA2877584A1 (en) 2014-01-03
SG11201408196RA (en) 2015-03-30
IL236428A0 (en) 2015-02-26
US9163070B2 (en) 2015-10-20
US20150368302A1 (en) 2015-12-24
EP2867360B1 (en) 2019-05-08
CN104508129A (zh) 2015-04-08
EP2867360A1 (en) 2015-05-06
HK1209156A1 (en) 2016-03-24
RU2014150224A (ru) 2016-08-20
MX2014015825A (es) 2015-08-10
JP2015522576A (ja) 2015-08-06
WO2014001442A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
IN2014MN02522A (enExample)
BR112014029417A2 (enExample)
BR112014017635A2 (enExample)
BR112014023806A2 (enExample)
BR112014017625A2 (enExample)
BR112014017659A2 (enExample)
BR112014017646A2 (enExample)
BR112014017638A2 (enExample)
AR092201A1 (enExample)
BR112014023567A2 (enExample)
BR112014017974A2 (enExample)
BR112013027865A2 (enExample)
BR112014019700A2 (enExample)
BR112014017634A2 (enExample)
BR112014017644A2 (enExample)
BR112014018153A2 (enExample)
BR112014017647A2 (enExample)
BR112014013184A8 (enExample)
BR112014017623A2 (enExample)
BR112014017652A2 (enExample)
BR112014017630A2 (enExample)
BR112014017627A2 (enExample)
BR112014017621A2 (enExample)
BR112014017631A2 (enExample)
BR112014017641A2 (enExample)